Revive Therapeutics Ltd C.RVV

Alternate Symbol(s): RVVTF

Healthcare

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).

CSE:RVV - Post by User

Revive Therapeutics Ltd > 2017 High broken

<< Previous

Bullboard Posts

Next >>

Comment by Bullchart1on Dec 13, 2020 9:06pm

202 Views

Post# 32097095

RE:2017 High broken

Bullchart1 wrote: And on no news today. Head over to the 2014 and 2015 highs as a target down the road now.

Watch the stop sell orders we have in here. Just might jump up and take them out.

Expect a follow-up on Phase 3 FDA

Revive Therapeutics Ltd. has appointed Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical adviser to the company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the continuing U.S. Food & Drug Administration (FDA) phase 3 clinical trial to evaluate the safety and efficacy of bucillamine in patients with mild to moderate COVID-19.

<< Previous

Bullboard Posts

Next >>

Osisko Development receives permits for Cariboo Gold Project